XTX Topco Ltd Has $642,000 Stake in Apogee Therapeutics Inc. (NASDAQ:APGE)

Key Points

• XTX Topco Ltd increased its shares in Apogee Therapeutics by 170.8% in Q1, holding a total of 17,188 shares valued at $642,000.
• Several analysts have set new price targets for Apogee Therapeutics, with a consensus target of $99.00 and multiple buy ratings from firms like BTIG Research and Guggenheim.
• On July 2nd, insider Carl Dambkowski sold 10,090 shares for over $454,000, reducing his ownership by 4.05% but still holding 238,998 shares valued at approximately $10.78 million.

XTX Topco Ltd grew its stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 170.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 17,188 shares of the company's stock after buying an additional 10,840 shares during the period. XTX Topco Ltd's holdings in Apogee Therapeutics were worth $642,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in Apogee Therapeutics in the fourth quarter valued at about $43,000. GAMMA Investing LLC increased its stake in Apogee Therapeutics by 3,560.1% in the first quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock valued at $202,000 after acquiring an additional 5,269 shares during the period. Optimize Financial Inc bought a new stake in Apogee Therapeutics in the fourth quarter valued at about $203,000. BNP Paribas Financial Markets bought a new stake in Apogee Therapeutics in the fourth quarter valued at about $219,000. Finally, Commonwealth Equity Services LLC bought a new stake in Apogee Therapeutics in the fourth quarter valued at about $222,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 2,725 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $37.78, for a total transaction of $102,950.50. Following the transaction, the insider directly owned 236,273 shares in the company, valued at approximately $8,926,393.94. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 15,540 shares of company stock worth $658,625 over the last quarter. 42.77% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. BTIG Research upped their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Guggenheim reissued a "buy" rating and issued a $116.00 target price on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. Wedbush reissued an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Monday, July 7th. Finally, Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, July 7th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $99.00.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock traded down $0.61 during trading hours on Friday, hitting $35.39. 622,255 shares of the stock were exchanged, compared to its average volume of 676,257. The stock has a market capitalization of $1.63 billion, a P/E ratio of -9.83 and a beta of 1.43. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The business's 50-day moving average is $40.18 and its two-hundred day moving average is $38.03.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, equities analysts predict that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.